Molecularly defined models of human childhood brain tumors
MYC proteins like MYC and MYCN are transcription factors that are mis-regulated in more than half of all types of human cancer including medulloblastoma, the most common brain malignancy in children. The two main challenges that c...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
ORIGIN4MB
Uncovering the cell of origin of Group 4 Medulloblastoma
157K€
Cerrado
SAF2014-53526-R
ONCOPROTEINAS MYC Y CTCF EN EL CONTROL TRANSCRIPCIONAL DE LA...
339K€
Cerrado
SAF2017-88026-R
INTERACCIONES FUNCIONALES DE MYC Y CTCF EN CELULAS DE LINFOM...
218K€
Cerrado
NeuroblastORG
Developing neural crest organoids with inducible neuroblasto...
158K€
Cerrado
GAMNG
Identification of the genetic and or epigenetic events that...
75K€
Cerrado
Información proyecto Medulloblastoma
Duración del proyecto: 60 meses
Fecha Inicio: 2015-04-23
Fecha Fin: 2020-04-30
Líder del proyecto
UPPSALA UNIVERSITET
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
1M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
MYC proteins like MYC and MYCN are transcription factors that are mis-regulated in more than half of all types of human cancer including medulloblastoma, the most common brain malignancy in children. The two main challenges that can guide research in the field of pediatric brain tumors is improving survival and reducing long-term detriments due to treatment toxicities, especially from craniospinal radiotherapy. Medulloblastoma is suggested to originate from specific cells in the small brain, cerebellum. These brain tumors have recently been classified into four distinct molecular subgroups and subgroup-specific driver genes have been suggested. However, the precise role of such drivers in tumor initiation and their importance in specifying particular subgroups has not been sufficiently evaluated in proper cells of medulloblastoma origin.
We have generated clinically relevant animal models that carefully resemble some of the defined subgroups of medulloblastoma. In this proposal we intend to use the models to identify the specific cell type these brain tumors originates from. We also aim to refine our medulloblastoma models and develop novel models to define and study cells involved in brain metastasis and tumor recurrence; the main cause of death in brain tumor patients.
We have managed to culture normal human cerebellar stem cells and we now plan to model human medulloblastoma development by overexpressing oncogenes or silencing suppressor genes that are defined as clinically relevant medulloblastoma drivers. We will use a forward genetics screen to identify novel drivers and specifiers of various subtypes of medulloblastoma. We hope these combined efforts will help us better model human medulloblastoma formation and we expect to generate tumors that correlate well, both pathologically and molecularly, with primary cell cultures derived from medulloblastoma patients.